GGrantIndex
Sort

8,912 grants matching sars cov 2

Regulation of antibody-mediated effector functions

$297,692
Taia Wang · Stanford University · U19 · FY2025 · AI

SARS-CoV2 Immunity and Cell Biology

$297,649
Jonathan W Yewdell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Africa Center for Biostatistical Excellence: Expanding biostatistical leadership for HIV/AIDS and TB Research

$297,464
Taryn Natalie Young · Stellenbosch University · D43 · FY2024 · TW

Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses

$297,402
Patricia Veronica Aguilar · University Of Texas Med Br Galveston · D43 · FY2023 · TW

Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses

$297,388
Patricia Veronica Aguilar · University Of Texas Med Br Galveston · D43 · FY2024 · TW

EAGER: Integrating Genotype, Phenotype, and Environment to Identify Biomarkers of Coronavirus Disease Severity and Transmission

$297,382
James Weger · Virginia Polytechnic Institute And State University · · FY2020 · BIO

Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses

$297,374
Patricia Veronica Aguilar · University Of Texas Med Br Galveston · D43 · FY2025 · TW

Research Core 1: Molecular Measures Core (RC1)

$297,334
Virginia B. Kraus · Duke University · P30 · FY2022 · AG

COVID-19 Instrumentation in the RTB

$297,252
James Cherry · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI

Humanization of ACE2 and Associated Priming Proteases in New Mouse Models for Downstream Disease and Therapy Investigations of COVID-19

$297,204
Wei Weng · Ingenious Targeting Laboratory, Inc. · R43 · FY2021 · AI

Large scale in vitro production of capped polyadenylated mRNA-based vaccines in solid phase using immobilized enzymes

$297,193
Maria Kireeva · Affinity Molecules, Llc · R43 · FY2021 · TR

TRANSMIT: Training Research Acumen iN Students Modeling Infectious Threats

$297,120
Lindsay T. Keegan · University Of Utah · U01 · FY2022 · CK

Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)

$297,077
W. Henry Henry Boom · Case Western Reserve University · D43 · FY2024 · TW

Core-- Animal Models

$297,062
University Of North Carolina Chapel Hill · P01 · FY2005 · AI

Nanobody toolkit for human coronavirus classification

$297,000
Andrew Hayhurst · Texas Biomedical Research Institute · R21 · FY2021 · AI

Africa Center for Biostatistical Excellence: Expanding biostatistical leadership for HIV/AIDS and TB Research

$296,960
Taryn Natalie Young · Stellenbosch University · D43 · FY2025 · TW

Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses

$296,935
Patricia Veronica Aguilar · University Of Texas Med Br Galveston · D43 · FY2022 · TW

New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists

$296,931
Barry A Berkowitz · Bessor Pharma, Llc · R43 · FY2024 · AI

Animal/Virology Core

$296,888
Stanley Perlman · University Of Iowa · P01 · FY2017 · AI

Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)

$296,809
W. Henry Henry Boom · Case Western Reserve University · D43 · FY2023 · TW

Animal/Virology Core

$296,783
Stanley Perlman · University Of Iowa · P01 · FY2021 · AI

Animal/Virology Core

$296,783
Stanley Perlman · University Of Iowa · P01 · FY2020 · AI

Animal/Virology Core

$296,782
Stanley Perlman · University Of Iowa · P01 · FY2019 · AI

An L-Aptamer-Displacement Assay for High-Throughput Screening of RNA-Targeted Small Molecule Antivirals

$296,650
Jonathan Thomas Sczepanski · Texas A&M University · R21 · FY2024 · AI

Targeting galectin-3 to intervene COVID-19

$296,637
Hafiz Ahmed · Glycomantra, Inc. · R43 · FY2023 · AI